Etoposide-based rechallenge and second/third line treatments in patients with metastatic neuroendocrine carcinoma: Results from the multicenter RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

#3420

Introduction: Neuroendocrine carcinomas (NEC) are aggressive malignant diseases. Etoposide-based rechallenge (EBR) and the prognostic role of Rb status in second-line (SL) have not been studied.

Aim(s): To report the results of second and third-line treatments (Trt) and putative prognostic factors in the RBNEC study population.

Materials and methods: This retrospective study involved seven French centers. NEC patients (pts) treated in second-line and further whatever the primary and with tissue samples available were included. Rb status and pathology were reviewed centrally.

Conference:

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Walter T, Hescot S, Hautefeuille V,

Keywords: Neuroendocrine carcinoma, Rb, rechallenge,